ROQUMEDIA
25.4.2022 16:42:09 CEST | Business Wire | Press release
ROQUMedia:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220425005564/en/
FLOYD MAYWEATHER:
https://twitter.com/FloydMayweather/status/1517594581373648896?s=20&t=dEEnqLrQWsybIa81CA-JJA
Global Titans Fight Series announced the WORLD’S FIRST EVER NFT SPORTS event will give access to an exclusive livestream pay-per-view for NFT ticket holders. The Global Titans NFT tickets are considered a historic moment, where sports and tech fans take a giant leap forward, changing the way one interacts with live entertainment.
The NFT ticket will give access to watch Global Titans Dubai live online on May 14th , where an epic night of boxing on the helipad of the iconic Burj Al Arab Jumeirah hotel. The spectacular event boasts an explosive line-up including star champions Floyd Mayweather, Anderson Silva and many more.
A landmark moment for international sports, fans buying the NFT will also acquire a special Global Titans NFT ticket, that is highly collectable. More than an event ticket, NFT technology provides buyers with unique features such as future access, rewards and more – all that increase the value of its ownership long after the event.
Developing special technologies, ROQUMedia and Yakomoz Events, the founders of Global Titans, have teamed up with Web3 experts, MintGate for this NFT. Buyers will be able to watch the livestream of these inaugural fights directly from anywhere in the world without requiring access codes or passwords. NFT owners can simply connect their crypto wallets (such as MetaMask) for instant access.
Additionally, owners of this NFT will be able to unlock Limited Edition 3D collectibles, special video content and official media from the event.
There are two Global Titans NFT tickets now available to the public.
- 80,000 collectible NFTs with PPV access in the Polygon Matic or payable by credit card.
- Currently 10 highly exclusive ringside seat NFTs are available to attend this event in person.
Seat to attend the event and collectable NFT ticket Pay-Per-View livestream are available at www.globaltitans.com
“MintGate is hyper-focused on making digital ownership accessible to anyone in the world,” said Jonathan Dunlap (CEO). “To further this mission, we launched a revolutionary way to purchase a NFT directly with a credit card,” continued Matt Hoffman (CSO).
Robert Quirke, ROQUMedia (CEO) stated: “For many people, this will be the first time they will buy an NFT. We made sure to provide them with great value, by including exciting digital assets that can be traded and combined to watch the Floyd Mayweather fight livestream online. The live event on May 14th will be known as an international turning point where live sports and entertainment embraced the next generation of technology. The PPV tickets use the Polygon Blockchain & MATIC, as this offers fans the lowest gas fees, making them significantly more environmentally friendly.”
GLOBAL TITANS
Global Titans Dubai is the first in series of special boxing and MMA events which will be staged at iconic locations across four continents. Each main event is broadcast globally, featuring champion fighters and exclusive collectable NFT tickets.
Seat to attend the event and collectable NFT ticket Pay-Per-View livestream : www.globaltitans.com
MINTGATE
MintGate is a proven web3 platform for building membership-based communities and elevating the relationship between people and the brands they care about. We bring people closer to the future by unlocking the value of digital ownership.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20220425005564/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom